Neuroscience technology company Cambridge Cognition Holdings plc (AIM: COG) has entered into a commercialisation agreement with Nostalgic Dust Private Limited, trading as Ivory, to deploy CANTAB Pathway across professional healthcare and consumer health markets in India.

This agreement positions CANTAB Pathway for scaled rollout through Ivory's clinical network, consumer platform and partnerships spanning hospitals, clinics and health-tech ecosystems. Assessments are currently available in English and multiple Indian languages including Hindi, Tamil, Telugu, Bengali and Kannada, with further expansion planned.

India presents a significant growth opportunity, with a population of approximately 1.47 billion. Research indicates that of 138 million people aged over 60, as many as 34 million may be living with mild or major cognitive impairment, while studies suggest up to 90% of cases remain underdiagnosed. Expanding middle and affluent demographic, estimated at 90-190 million people, is increasingly focused on longevity, healthspan and access to high-quality healthcare.

The partnership supports Cambridge Cognition's strategy to expand into high-growth international healthcare and consumer markets, leveraging Ivory's rapidly scaling brain health platform. Ivory recently published India's first Brain Health Report and offers an FDA-registered cognitive assessment alongside personalised brain training via its app.

CANTAB Pathway comprises an escalating series of digital cognitive assessments, including CANTAB One, CANTAB Insight and CANTAB Plus, covering eight indications such as Parkinson's disease, attention deficit hyperactivity disorder, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias.

Cambridge Cognition develops touchscreen and voice-based cognitive assessments under the CANTAB and Winterlight brands, designed to deliver objective, low-burden, real-time results suitable for consumer, clinical and research settings.